Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Dec;47(6):1902-1917.
doi: 10.1007/s10753-024-02018-1. Epub 2024 Apr 26.

Bacillus Calmette-Guérin (BCG)-Induced Protection in Brain Disorders

Khiany Mathias  1   2 , Richard Simon Machado  2   3 , Solange Stork  2 , Carla Damasio Martins  2 , Amanda Christine da Silva Kursancew  2 , Victória Linden de Rezende  2 , Cinara Ludvig Gonçalves  2 , Tatiana Barichello  2   4 , Josiane Somariva Prophiro  1 , Fabricia Petronilho  5   6
Affiliations
Review

Bacillus Calmette-Guérin (BCG)-Induced Protection in Brain Disorders

Khiany Mathias et al. Inflammation. 2024 Dec.

Abstract

The Bacille Calmette-Guerin (BCG) vaccine is one of the most widely used vaccines in the world for the prevention of tuberculosis. Its immunological capacity also includes epigenetic reprogramming, activation of T cells and inflammatory responses. Although the main usage of the vaccine is the prevention of tuberculosis, different works have shown that the effect of BCG can go beyond the peripheral immune response and be linked to the central nervous system by modulating the immune system at the level of the brain. This review therefore aims to describe the BCG vaccine, its origin, its relationship with the immune system, and its involvement at the brain level.

Keywords: BCG vaccine; Brain; Immune response; Inflammation.

PubMed Disclaimer

Conflict of interest statement

DECLARATIONS. Ethics Approval: Not applicable Consent to Participate: Not applicable Consent for Publication: Not applicable Competing Interests: The authors declare no competing interests.

References

    1. Andersen, P., and T.M. Doherty. 2005. The success and failure of BCG — implications for a novel tuberculosis vaccine. Nature Reviews. Microbiology 3 (8): 656–662. - PubMed - DOI
    1. Fatima, S., A. Kumari, G. Das, and V.P. Dwivedi. 2020. Tuberculosis vaccine: a journey from BCG to present. Life Sciences 252: 117594. - PubMed - DOI
    1. Moreo, E., A. Jarit-Cabanillas, I. Robles-Vera, S. Uranga, C. Guerrero, A.B. Gómez, et al. 2023. Intravenous administration of BCG in mice promotes natural killer and T cell-mediated antitumor immunity in the lung. Nature Communications 14 (1): 6090. - PubMed - PMC - DOI
    1. Tran, Kim A., E. Pernet, M. Sadeghi, J. Downey, J. Chronopoulos, E. Lapshina, O. Tsai, E. Kaufmann, J. Ding, and M. Divangahi. 2024. BCG immunization induces CX3CR1hi effector memory T cells to provide cross-protection via IFN-γ-mediated trained immunity. Nature Immunology 25: 418–431
    1. Jeyanathan, M., M. Vaseghi-Shanjani, S. Afkhami, J.A. Grondin, A. Kang, M.R. D’Agostino, et al. 2022. Parenteral BCG vaccine induces lung-resident memory macrophages and trained immunity via the gut–lung axis. Nature Immunology 23 (12): 1687–1702. - PubMed - PMC - DOI

LinkOut - more resources